ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line, providing Immediate Immunity for the prevention of scours in newborn dairy and beef calves. It expanded this line into four different products with formulations targeting E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. This product line provides Immediate Immunity to newborn calves. The Company is engaged in the development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. The Company’s products reduce the use of traditional antibiotics in food producing animals.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)